


Webinar at Creative BioMart: Single Cell Analysis of Response and Toxicity Following CD19 CAR T-Cell Therapy in Lymphoma

Creative BioMart announces that it will host a webinar entitled: Single Cell Analysis of Response and Toxicity Following CD19 CAR T-Cell Therapy in Lymphoma.

SHIRLEY, NY, US, May 9, 2023 /EINPresswire.com/ -- <u>Creative BioMart</u>, one of the superior life science companies focusing on recombinant proteins and related services, announces that it will host a webinar



entitled: Single Cell Analysis of Response and Toxicity Following CD19 CAR T-Cell Therapy in Lymphoma.

Large B cell lymphomas (LBCLs) that have relapsed or become resistant to treatment have shown a remarkable degree of benefit from autologous chimeric antigen receptor (CAR) T cell therapies that target CD19. Nevertheless, despite notable improvements in patient outcomes, the majority of patients do not experience long-lasting improvements, and adverse treatment effects like immune effector cell-associated neurotoxicity syndrome (ICANS) pose a significant clinical challenge.

The quality of the T-cells at the time of apheresis, the functional heterogeneity of the CAR T-cell infusion product that is associated with it, and characteristics of the tumor and tumor microenvironment that may restrict in vivo expansion and T-cell effector function are all possible causes of CAR T-cell therapy failure. A number of variables connected to the CAR T-cell product's activity and the host immune system work together to cause toxicities. Single cell RNA-sequencing (scRNA-seq) analysis of the various compartments (apheresis product, infusion product, post-infusion CAR T-cells, tumor) has been a key strategy for identifying mechanisms of resistance and toxicity.

The upcoming webinar will feature presentations from: Dr. Michael R. Green, Associate Professor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The

University of Texas MD Anderson Cancer Center, Houston, TX. The goal of the Green Laboratory is to develop novel therapeutic interventions that are motivated by a profound mechanistic understanding of healthy and malignant immune cell biology in order to increase the survival and quality of life for people with B-cell malignancies.

Creative BioMart invited Dr. Michael R. Green to provide an overview of scRNA-seq studies that have improved the understanding of CAR T-cell therapy and informed novel approaches to therapeutically target their mechanistic underpinnings.

The webinar will take place on 3PM CDT / 4PM EDT / 1PM PDT, May 24, 2023. And the <u>registration link</u> is: https://www.creativebiomart.net/single-cell-analysis-of-response-and-toxicity-following-cd19-car-t-cell-therapy-in-lymphoma.htm.

About Creative BioMart

Creative BioMart has always focused on developing high-quality protein products and efficient protein manufacturing techniques. Over the past decade, our products and services have been proven to have served our customers well and our brand has become one of the most trustworthy in the market. We specially provide a list of high-quality CAR T-cell therapy target proteins for you.

Caroline Green
Creative BioMart
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/632372068

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.